siRNA Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 3.1 billion
Estimated Base Value
2035 Forecast
US$ 22.2 billion
Projected Market Value
CAGR 2026–2035
21.8%
Compound Annual Growth
Largest Segment
Chemically Modified siRNA
Fastest Growing Segment
Conjugated Sirna
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
35.0% market share
Key Players
Alnylam Pharmaceuticals
Emerging Players
ADARx Pharmaceuticals, Aligos Therapeutics
Market Definition & Overview
The siRNA Therapeutics market encompasses the research, development, manufacturing, and commercialization of pharmaceutical products utilizing small interfering RNA (siRNA) technology. These therapeutics are designed to harness the natural RNA interference (RNAi) pathway to silence specific disease-causing genes at the post-transcriptional level, thereby inhibiting the production of detrimental proteins. This market primarily targets the treatment of various diseases including genetic disorders, oncology, infectious diseases, and neurological conditions, representing a significant advancement in precision medicine within the broader RNA therapeutics industry.
Scope
- Global market analysis across major regions and countries.
- Segmentation by disease application, delivery technology, and end-user.
- Comprehensive market sizing and forecast from 2023 to 2033.
Inclusions
- Approved small interfering RNA (siRNA) drugs for human therapeutic use.
- siRNA drug candidates in various stages of clinical development.
- Delivery technologies specifically developed for siRNA therapeutics.
- Manufacturing and supply chain activities for siRNA products.
- Revenue from sales of commercialized siRNA therapeutic agents.
- R&D expenditure focused on novel siRNA mechanisms and targets.
Exclusions
- Antisense oligonucleotide (ASO) therapies and mRNA vaccines.
- siRNA research reagents and diagnostic kits.
- CRISPR-Cas9 or other gene-editing technologies.
- Exosomes or viral vector-based gene therapies unrelated to siRNA.
- Traditional small molecule drugs or protein biologics.
- Non-therapeutic applications of RNA interference.
Market Size Forecast
Executive Summary
• The siRNA Therapeutics market is valued at $3.1 Bn in 2025 and is forecast to reach $22.2 Bn by 2035, reflecting a robust CAGR of 21.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Chemically Modified siRNA leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 38.5%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 35.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competition from emerging biotech and established pharmaceutical giants is driving strategic collaborations and targeted M&A, reshaping the siRNA landscape through advanced delivery system innovations and pipeline diversification across rare and chronic diseases.
• Expanded therapeutic applications beyond rare diseases, particularly into chronic conditions like cardiovascular and metabolic disorders, alongside advancing delivery technologies, will fuel sustained long-term market expansion and investment opportunities globally.
• Breakthroughs in extrahepatic delivery and gene editing integration are critical technological advancements, navigating evolving regulatory pathways that prioritize safety and efficacy while accelerating novel siRNA therapeutic approvals across key regions.
• The oncology and CNS segments represent significant untapped potential, demanding region-specific R&D investments and tailored market access strategies to overcome delivery challenges and address unmet medical needs effectively.
• Robust investment in specialized manufacturing capabilities and cold chain logistics is essential, ensuring scalable production and global distribution efficiency for novel siRNA therapies as pipeline assets approach commercialization.
• Successful market penetration hinges on demonstrating superior long-term efficacy and patient convenience, compelling innovators to differentiate through proprietary delivery platforms and strategic portfolio expansion in high-growth therapeutic areas.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The siRNA Therapeutics Market was valued at $3.1 billion in its base year, establishing a significant foundation for future expansion.
Future Market Scale
The market is projected to reach an impressive $22.2 billion by the forecast year, indicating substantial growth and increasing therapeutic adoption.
Exceptional Growth Rate
A robust Compound Annual Growth Rate (CAGR) of 21.8% highlights the rapid expansion and escalating demand for siRNA-based therapies.
Substantial Market Growth
Overall, the market is set for nearly a seven-fold expansion, growing from $3.1 billion to $22.2 billion, driven by scientific advancements.
Therapeutic Area Expansion
Expansion into novel therapeutic areas, particularly rare genetic disorders and chronic diseases, represents a leading segment driving market growth.
Delivery System Innovations
A notable trend fueling market development is continuous innovation in siRNA delivery systems, improving efficacy and patient accessibility.
Market Dynamics
Market Trends
- Increased R&D for novel siRNA delivery systems.
- Growing focus on extrahepatic targets beyond liver.
- Expansion into chronic diseases and rare genetic disorders.
- Strategic collaborations and partnerships are becoming common.
Growth Drivers
- Rising prevalence of genetic and chronic diseases.
- Advancements in RNA interference technology and delivery.
- Increased investment and funding in biotech sector.
- Favorable regulatory landscape supporting orphan drugs.
Restraints
- Efficient and specific delivery of siRNA to target cells remains a significant challenge.
- High development and manufacturing costs hinder broader market adoption.
- Potential for off-target effects and immunogenicity raises safety concerns.
- Complex regulatory pathways and stringent approval processes impede market entry.
Opportunities
- Developing siRNA therapies for previously untreatable conditions.
- Exploring combination therapies to enhance efficacy.
- Expanding applications into oncology, neurology, and infectious diseases.
- Leveraging AI/ML for drug discovery and target identification.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Chemically Modified SirnaUnmodified SirnaConjugated SirnaSelf-Delivering SirnaDicer Substrate Sirna |
| By Application | OncologyGenetic DisordersInfectious DiseasesCardiovascular DiseasesNeurological DisordersOcular DiseasesLiver DiseasesOthers |
| By Technology | Lipid NanoparticlesGalnac ConjugatesPolymer-Based Delivery SystemsViral VectorsExosome-Based DeliveryPeptide ConjugatesAntibody ConjugatesOthers |
| By End-User | HospitalsSpecialty ClinicsResearch & Academic InstitutionsBiopharmaceutical CompaniesContract Research OrganizationsDiagnostic Laboratories |
| By Form | Injectable FormulationsTopical FormulationsOcular FormulationsPulmonary FormulationsOral FormulationsImplantable Devices |
| By Stage | Discovery and Pre-Clinical StagePhase I Clinical TrialsPhase II Clinical TrialsPhase III Clinical TrialsCommercialized Products |
Regional Analysis
- North America leads the siRNA therapeutics market due to substantial R&D investments, a robust presence of major pharmaceutical companies, and a favorable regulatory environment. High healthcare expenditure and advanced infrastructure also significantly contribute to its dominance.
- Asia-Pacific is emerging as the fastest-growing region, driven by the escalating prevalence of chronic diseases and increasing healthcare expenditure. Expanding pharmaceutical R&D, rising patient awareness, and government initiatives supporting biotechnology advancements fuel this rapid market expansion.
- Europe demonstrates a noteworthy trend with an increasing focus on developing siRNA therapies for rare genetic diseases and personalized medicine approaches. Collaborative research initiatives between academic institutions and biotech firms, coupled with government funding, are driving innovation in this specialized segment.
Asia Pacific
9.5% CAGR
$713.0 Mn
23% share
- The Asia Pacific region is rapidly expanding, fueled by rising healthcare expenditure, increasing incidence of chronic diseases, and growing R&D activities in countries like China, Japan, and India.
North America
7.8% CAGR
$1.2 Bn
38.5% share
- North America leads the siRNA therapeutics market due to significant R&D investments, a strong presence of key pharmaceutical and biotech companies, and advanced healthcare infrastructure.
Europe
7.5% CAGR
$868.0 Mn
28% share
- Europe holds a substantial share, driven by robust research funding, a well-established pharmaceutical industry, and increasing regulatory support for novel RNA-based therapies.
Latin America
8.8% CAGR
$170.5 Mn
5.5% share
- Latin America demonstrates promising growth in siRNA therapeutics, attributed to improving healthcare access, increasing awareness of advanced treatments, and a growing patient pool in key markets such as Brazil and Mexico.
Middle East & Africa
9.8% CAGR
$93.0 Mn
3% share
- This region exhibits high growth potential from a smaller base, driven by increasing government investments in healthcare infrastructure and a rising demand for advanced therapies for genetic and chronic diseases.
Emerging Areas
10.5% CAGR
$62.0 Mn
2% share
- Emerging Areas, encompassing smaller, nascent geographies, are showing the highest CAGR due to low market penetration, expanding healthcare initiatives, and increasing global accessibility of siRNA treatments.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $1.1 Bn | 9.5% | The U.S. leads the siRNA therapeutics market due to extensive R&D investments, a robust biotech ecosystem, and a concentration of major pharmaceutical companies driving innovation and commercialization. |
| 2 | Brazil | $55.8 Mn | 13.0% | As the largest economy in South America, Brazil presents a significant patient population and increasing investment in its healthcare sector, making it a growing market for advanced therapies. |
| 3 | Germany | $217.0 Mn | 9.0% | Germany's robust pharmaceutical industry, advanced healthcare system, and strong research infrastructure position it as a key European market for siRNA therapeutics development and adoption. |
| 4 | China | $285.2 Mn | 15.0% | China is experiencing rapid growth in its biotech sector, fueled by massive patient populations, increasing R&D investment, and strong government support for innovative drug development, including siRNA. |
| 5 | Saudi Arabia | $24.8 Mn | 11.5% | Saudi Arabia is increasing its healthcare spending and actively developing its local pharmaceutical industry and research capabilities, driving demand for innovative treatments like siRNA. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Arrowhead Pharmaceuticals | 6% | Utilizes its proprietary TRiM platform to deliver RNAi therapeutics to various cell types, primarily targeting liver and lung diseases. | Known for its advanced TRiM (Targeted RNAi Molecule) platform, which allows for tissue-specific delivery of siRNA. | Expanded its collaboration with Takeda in 2021 for the development and commercialization of ARO-AAT for alpha-1 antitrypsin deficiency. | ARO-APOC3ARO-ANG3ARO-C3+1 |
| 2 | Silence Therapeutics | 5.7% | Develops novel siRNA therapeutics using its proprietary mRNAi GOLD platform, focusing on hematological and cardiovascular diseases. | Employs its unique mRNAi GOLD platform to create highly stable and potent siRNA therapeutics. | Reported positive Phase 2 data for SLN360 (targeting Lp(a)) in cardiovascular disease, progressing its lead candidate. | SLN360SLN124SLN501 |
| 3 | Avidity Biosciences | 5.4% | Pioneers the development of Antibody Oligonucleotide Conjugates (AOCs) to deliver RNA therapeutics to specific cell types and tissues beyond the liver. | Revolutionizing RNA therapeutics by combining antibodies with siRNAs to target extrahepatic tissues, overcoming previous delivery challenges. | Initiated Phase 1/2 trial for AOC 1001 for myotonic dystrophy type 1 (DM1), representing a significant step in their clinical advancement. | AOC 1001AOC 1020AOC 1044 |
| 4 | OliX Pharmaceuticals | 5.1% | Focuses on developing therapeutic siRNAs using its proprietary 'cell-permeable self-delivering RNAi (cp-siRNA)' technology for various diseases, including dermatology, ophthalmology, and oncology. | Utilizes a unique cp-siRNA technology that enables cellular uptake without delivery vehicles, enhancing safety and convenience. | Entered into a strategic partnership with Thea Open Innovation in 2021 for the development and commercialization of OLX301A for ophthalmic diseases. | OLX101OLX301AOLX702A |
| 5 | Sirnaomics | 4.7% | Develops RNAi therapeutics for a wide range of diseases, particularly oncology and fibrotic diseases, leveraging its proprietary pH-sensitive polymer nanoparticle (PNP) delivery system. | Has a dual-targeted siRNA candidate (STP705) that inhibits both TGF-β1 and COX-2, showing promise in various cancers and fibrotic conditions. | Announced positive Phase IIb data for STP705 in squamous cell carcinoma in situ (isSCC), moving closer to regulatory approval. | STP705STP707STP702 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (19)
Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, Sirnaomics, Arbutus Biopharma, ReCode Therapeutics, Quark Pharmaceuticals, Exicure, Ascletis Pharma, Suzhou Ribo Life Science, Bio-Path Holdings, TransCode Therapeutics, miCure Therapeutics, Veritas Therapeutic, Evrys Bio, AttoVax, Nurex Therapeutics, Genevant Sciences
The global siRNA Therapeutics market features a competitive landscape led by Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, and Sirnaomics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Arrowhead Pharmaceuticals
Silence Therapeutics
Avidity Biosciences
OliX Pharmaceuticals
Sirnaomics
Arbutus Biopharma
ReCode Therapeutics
Quark Pharmaceuticals
Exicure
Ascletis Pharma
Suzhou Ribo Life Science
Bio-Path Holdings
TransCode Therapeutics
miCure Therapeutics
Veritas Therapeutic
Evrys Bio
AttoVax
Nurex Therapeutics
Genevant Sciences
ADARx Pharmaceuticals
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Alnylam Reports Positive Phase 1 Data for Hypertension siRNA Therapeutic
Alnylam Pharmaceuticals announced promising Phase 1 results for ALN-K8, an investigational RNAi therapeutic targeting hypertension, demonstrating significant and sustained reductions in blood pressure and opening a potentially large new market.
Silence Therapeutics Enters Collaboration with Mallinckrodt for Rare Disease Program
Silence Therapeutics forged a strategic partnership and licensing agreement with Mallinckrodt for SLN501, an siRNA therapeutic targeting C3 for complement-mediated diseases, securing an upfront payment and potential milestone earnings.
Novartis Highlights Strong Global Uptake and Data for Leqvio (inclisiran)
Novartis, commercializing Alnylam's Leqvio (inclisiran), reported robust uptake and reiterated strong long-term efficacy and safety data from studies like ORION-8, solidifying the siRNA therapeutic's position in cardiovascular disease management.
Arrowhead and Takeda Advance Fazirsiran into Pivotal Phase 3 for AATD-LD
Arrowhead Pharmaceuticals, in collaboration with Takeda, provided updates on the continued advancement of their investigational siRNA therapeutic, fazirsiran, through pivotal Phase 3 trials for alpha-1 antitrypsin deficiency-associated liver disease, nearing potential market approval.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $3.1 Bn |
| Market Size (Forecast) | $22.2 Bn |
| CAGR | 21.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 19 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included